Pharma BD Deal Intelligence
CAT's phage-display science became the backbone of AstraZeneca's biologics R&D, but the deal's own economics were only ever rescued by flipping CAT's pre-existing Humira royalty for $700M weeks after close — the direct pipeline payoff (tralokinumab, and indirectly benralizumab via the later MedImmune deal) came a decade-plus later and mostly benefited licensees/AZ's broader MedImmune-era business, not a clean CAT-specific ROI.
Full analysis, sources & comparables →$1.3B price reflected CAT's status as 'jewel in the crown' of UK biotech, with proven Humira economics and clinical pipeline of four mAbs.
CAT's phage-display platform, which produced Humira and belimumab, was merged with MedImmune (acquired 2007) to form AZ's biologics R&D division - validating…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Antibody phage display platform; GBP 702M total; AZN already held 19.2%
CAT's phage-display science became the backbone of AstraZeneca's biologics R&D, but the deal's own economics were only ever rescued by flipping CAT's pre-existing Humira royalty for $700M weeks after close — the direct pipeline payoff (tralokinumab, and indirectly benralizumab via the later MedImmune deal) came a decade-plus later and mostly benefited licensees/AZ's broader MedImmune-era business, not a clean CAT-specific ROI.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Cambridge Antibody Technology Group plc (this deal) | 2006 | $1.3B | 67 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2006 deals · AstraZeneca PLC deals